Aktienanalyse zu Organogenesis Holdings Inc (ORGO)ORGOOrganogenesis Holdings Inc

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $0.7555 and the RSI at 8.085, which indicates extreme oversold conditions, it may seem attractive. However, the stock has a significant 5-day change of -19.23% and a year-to-date decline of -83.70%, reflecting severe underlying issues. The recent earnings report showed a net loss of $56.2 million in Q1 2026, and the company is facing a challenging outlook with expected revenue declines of 45% to 52% for the year. The main risk is the forward P/E ratio of 12.67, indicating that while the stock is cheap, it may not be a good buy due to deteriorating fundamentals and uncertain future performance.